4D Molecular Therapeutics FDMT Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $60.24M-59.7% | $149.34M-40.1% | $249.11M+376% | $52.35M-65.8% | ||
| $342.41M+24.3% | $275.54M+604% | $39.12M-75.7% | $161.2M+70.1% | ||
| $413.13M-5.0% | $434.93M+46.6% | $296.59M+34.5% | $220.51M-14.0% | ||
| $14.87M-23.9% | $19.53M-2.9% | $20.13M-9.6% | $22.26M+54.7% | ||
| $566.71M+1.1% | $560.38M+64.9% | $339.89M+29.8% | $261.85M-25.9% | ||
| $30.87M+106% | $14.96M+5.9% | $14.13M+30.8% | $10.8M-7.9% | ||
| $360K+40.1% | $257K-5.9% | $273K-69.1% | $884K-66.0% | ||
| $43.99M+50.9% | $29.15M+53.8% | $18.95M+20.5% | $15.73M-3.7% | ||
| $61.05M+22.6% | $49.78M+55.3% | $32.06M+5.1% | $30.51M-11.3% | ||
| $6K+20.0% | $5K+25.0% | $4K+33.3% | $3K0.0% | ||
| -$716.3M-24.3% | -$576.2M-38.7% | -$415.33M-32.1% | -$314.49M-51.9% | ||
| $505.66M-1.0% | $510.61M+65.9% | $307.83M+33.1% | $231.34M-27.5% | ||
| $566.71M+1.1% | $560.38M+64.9% | $339.89M+29.8% | $261.85M-25.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $512.9M in total assets, down 0.5% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $20.5M in total debt against $451.8M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $72.5M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 9.34 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
